Drug Trial Radar · NCT07644377
Discontinuation Versus Continuation of Riociguat Monotherapy in Chronic Thromboembolic Pulmonary Hypertension Successfully Treated With Balloon Pulmonary Angioplasty
Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Nov 1, 2026
Primary completion
Jan 31, 2031
Study completion Jan 31, 2031
Sponsor
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but severe complication of acute pulmonary embolism, characterized by persistent obstruction of the pulmonary arteries by organized thrombi and secondary microvasculopathy. International guidelines recommend a multimodal approach combining pulmonary endarterectomy (PEA), balloon pulmonary angioplasty (BPA), and medical treatment with riociguat, to address the full spectrum of CTEPH lesions. BPA and riociguat are recommended for symptomatic patients with inoperable CTEPH or persistent pulmonary hypertension after PEA. Riociguat is administered before BPA to reduce periprocedural complications by improving pulmonary hemodynamics. While this pre-BPA strategy is well established, post-BPA management is poorly studied, especially in patients achieving therapeutic goals, defined as WHO functional class I or II and near-normal resting pulmonary hemodynamics (70 to 80% of cases). In such cases, riociguat monotherapy is often continued long-term, despite its cost, burden, and potential side effects, which may negatively impact patients' quality of life. Retrospective single-center studies suggest that discontinuation of medical treatment does not lead to significant clinical deterioration. Therefore, we propose conducting a multicenter trial using a PROBE (prospective, randomized, open-label, blinded endpoint) design and a Bayesian approach to test if stopping riociguat monotherapy after successful BPA is associated with an acceptably low risk of clinical worsening over a follow-up period of at least one year compared to continuation. The trial will also assess the cost-effectiveness of riociguat discontinuation.
Conditions
- CTEPH
Interventions
Discontinuation of riociguatDrug
Discontinuation of riociguat after randomization
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate whether the discontinuation of riociguat monotherapy after successful BPA in CTEPH patients is associated with an acceptably low risk of clinical worsening compared to continuationTime frame: At the longest follow-up, minimum 12 months
Locations
22 sites in 1 country. Site status is shown where the registry gives one.
CHU Angers
Angers, France
Hôpital Haut Levêque
Bordeaux, France
Hôpital de la Cavale blanche
Brest, France
CHU Caen
Caen, France
Hôpital Gabriel Montpied
Clermont-Ferrand, France
CHU Dijon Bourgogne
Dijon, France
CHU Grenoble Alpes
Grenoble, France
Hôpital Bicêtre
Le Kremlin-Bicêtre, France
Institut Cœur-Poumon
Lille, France
Hôpital de la Timone
Marseille, France
Hôpital Nord
Marseille, France
CHU Montpellier
Montpellier, France
Hôpital Laënnec
Nantes, France
Hôpital Européen Georges Pompidou
Paris, France
CHU Poitiers
Poitiers, France
Hôpital Pontchaillou
Rennes, France
CHU Rouen
Rouen, France
CHU Saint Etienne
Saint-Etienne, France
Nouvel Hôpital Civil
Strasbourg, France
Hôpital Larrey
Toulouse, France
Hôpital Bretonneau
Tours, France
Hôpital Brabois
Vandœuvre-lès-Nancy, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.